文献速递神经核医学肿瘤 PET/CT

代谢网络作为监测帕金森病脑深部电刺激治疗的客观生物标志物:纵向研究

Metabolic network as an objective biomarker in monitoring deep brain stimulation for Parkinson's disease: a longitudinal study.
PubMed 文献 · EJNMMI Res · 2020-10-29

本研究探讨18F-FDG PET衍生的帕金森病相关代谢协变模式(PDRP)在监测丘脑底核脑深部电刺激(STN DBS)治疗帕金森病中的可行性。33例PD患者、33例健康对照、9例双侧DBS术后PD患者及9例对照接受18F-FDG PET扫描,DBS患者纵向随访。结果显示PD患者PDRP表达异常升高(P<0.001),STN DBS治疗后3个月UPDRS(P=0.001)和PDRP表达(P=0.004)显著下降,12个月时两者均回升(均P<0.01),PDRP变化与UPDRS改善基本一致。

要点

  • PD患者PDRP表达较健康对照异常升高(P<0.001)
  • STN DBS后3个月UPDRS(P=0.001)与PDRP表达(P=0.004)显著下降
  • 12个月时UPDRS与PDRP表达均回升(均P<0.01),变化与UPDRS改善基本一致

核心结论

  • 代谢网络表达有潜力作为评估和监测PD患者STN DBS治疗的补充客观生物标志物。

研究设计与样本

  • 年龄匹配的33例PD患者、33例健康对照、9例双侧DBS术后PD患者和9例对照接受18F-FDG PET扫描。
  • DBS患者接受纵向随访,以观察PDRP表达的变化。

主要发现

  • PD患者PDRP表达较健康对照异常升高(P<0.001)。
  • STN DBS治疗后3个月,UPDRS(P=0.001)和PDRP表达(P=0.004)显著下降。
  • 治疗12个月后,UPDRS和PDRP表达均出现回升(均P<0.01)。
  • STN DBS介导的PDRP表达变化与UPDRS改善基本一致。
  • 图形网络分析显示3个月时连接增加、12个月时恢复,并由小世界系数证实。

临床怎么用

  • 18F-FDG PET衍生的PDRP表达可作为STN DBS治疗监测的补充客观指标,与UPDRS联合评估。

局限性

  • 结果为初步发现,DBS患者样本量较小(9例),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the advance of subthalamic nucleus (STN) deep brain stimulation (DBS) in the treatment of Parkinson's disease (PD), it is desired to identify objective criteria for the monitoring of the therapy outcome. This paper explores the feasibility of metabolic network derived from positron emission tomography (PET) with 18F-fluorodeoxyglucose in monitoring the STN DBS treatment for PD. METHODS: Age-matched 33 PD patients, 33 healthy controls (HCs), 9 PD patients with bilateral DBS surgery and 9 controls underwent 18F-FDG PET scans. The DBS patients were followed longitudinally to investigate the alternations of the PD-related metabolic covariance pattern (PDRP) expressions. RESULTS: The PDRP expression was abnormally elevated in PD patients compared with HCs (P < 0.001). For DBS patients, a significant decrease in the Unified Parkinson's Disease Rating Scale (UPDRS, P = 0.001) and PDRP expression (P = 0.004) was observed 3 months after STN DBS treatment, while a rollback was observed in both UPDRS and PDRP expressions (both P < 0.01) 12 months after treatment. The changes in PDRP expression mediated by STN DBS were generally in line with UPDRS improvement. The graphical network analysis shows increased connections at 3 months and a return at 12 months confirmed by small-worldness coefficient. CONCLUSIONS: The preliminary results demonstrate the potential of metabolic network expression as complimentary objective biomarker for the assessment and monitoring of STN DBS treatment in PD patients. Clinical Trial Registration ChiCTR-DOC-16008645. http://www.chictr.org.cn/showproj.aspx?proj=13865 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ge J, Wang M, Lin W, et al. Metabolic network as an objective biomarker in monitoring deep brain stimulation for Parkinson's disease: a longitudinal study. EJNMMI Res. 2020. PMID: 33119814. doi:10.1186/s13550-020-00722-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。